The Global Health Body Sounds Concern Over Critical Lack of Weight-Loss Injections

Fewer than 10% of individuals who could benefit from GLP-1 drugs including Wegovy have access to them, states the World Health Organization as it releases its initial recommendations on the therapies.

Given more than one billion people worldwide now living with obesity, it is urging increased and just access to these injectable treatments.

Per projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.

"The new guidelines affirms that excess weight is a chronic disease that can be managed with comprehensive and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and supply-chain constraints are major obstacles to widespread availability to the treatments that can aid individuals in losing significant body mass, notes the body.

Skinny Jab Supply Crisis

Even under the present most favorable scenario, the supply of these medications might only reach about 100 million people – less than 10% of those who need them, per the health organization.

The recommendation urges governments and firms to increase access, via approaches such as voluntary licensing.

A patent on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.

The Way Weight-Loss Jabs Function

GLP-1 drugs imitate a biological compound to reduce digestion speed, reduce hunger and boost feelings of fullness so people eat less.

Individuals usually begin shedding pounds within a few weeks of starting on the weekly injections.

Studies indicates people may regain a significant portion within a year of stopping the treatment, when their usual food cravings resume.

To be above a healthy weight increases your likelihood for experiencing medical conditions, such as diabetes, heart disease, brain attack, and specific malignancies.

Obesity impacts people in every country and was associated with millions of fatalities worldwide in 2024, per the health agency.